Program Type: New England CEPAC

Post-Traumatic Stress Disorder

May 2024 | Assessment

Interventions of Interest Post-traumatic stress disorder (PTSD) is a complex psychiatric disorder associated with substantial disability and poor quality of life that occurs in people who have experienced or witnessed one or more traumatic events. Traumatic events can include natural disasters, serious accidents, war and combat, rape and sexual assault, intimate partner violence and bullying. […]

Schizophrenia

Feb 2024 | Assessment

Interventions of Interest: The independent appraisal committee voted that current evidence is not adequate to demonstrate superior net health benefits for KarXT compared to generically available aripiprazole. If long-term data confirm KarXT’s benefits and lack of weight gain, it would achieve common thresholds for cost-effectiveness if priced between $16,000 to $20,000 per year. Final Documents […]

Multiple Sclerosis: CIS, RRMS, and SPMS

Jan 2023 | Assessment

An independent appraisal committee voted that evidence is not adequate to demonstrate a superior net health benefit for ublituximab when compared to other monoclonal antibodies. Analyses suggest ublituximab and all currently available monoclonal antibodies labeled for MS would achieve common thresholds for cost-effectiveness if priced between $16,500- $34,900 per year, a range far lower than […]

Obesity Management

Sep 2022 | Assessment

Interventions of Interest: The independent appraisal committee voted that evidence is adequate to demonstrate that semaglutide provides a net health benefit compared to lifestyle modification alone; however, at current pricing, semaglutide represents “low” long-term value for money. Semaglutide would only achieve common thresholds for cost-effectiveness if priced between $7,500 – $9,800 per year after rebates. […]